Welcome to LookChem.com Sign In|Join Free

CAS

  • or

240815-50-3

Post Buying Request

240815-50-3 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

240815-50-3 Usage

Chemical compound

6-CHLOROIMIDAZO[1,5-A]PYRIDO[3,2-E]PYRAZINE

Structure

Fused tetracyclic heteroaromatic compound containing a chloro-substituted imidazo[1,5-a]pyrido[3,2-e]pyrazine ring system

Properties

Investigated for potential biological and pharmacological activities, used as a building block in synthesis of pharmaceutical compounds

Importance

Valuable target for medicinal chemistry research and drug discovery efforts

Check Digit Verification of cas no

The CAS Registry Mumber 240815-50-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,4,0,8,1 and 5 respectively; the second part has 2 digits, 5 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 240815-50:
(8*2)+(7*4)+(6*0)+(5*8)+(4*1)+(3*5)+(2*5)+(1*0)=113
113 % 10 = 3
So 240815-50-3 is a valid CAS Registry Number.

240815-50-3Downstream Products

240815-50-3Relevant articles and documents

HETEROCYCLO-SUBSTITUTED IMIDAZOPYRAZINE PROTEIN TYROSINE KINASE INHIBITORS

-

Page/Page column 22, (2009/06/27)

Novel heterocyclo-substituted imidazopyrazines and salts thereof, pharmaceutical compositions containing such compounds, and methods of using such compounds in the treatment of protein tyrosine kinase-associated disorders such as immunologic disorders.

PYRIDO[3,2-e]PYRAZINES, THEIR USE AS INHIBITORS OF PHOSPHODIESTERASE 10, AND PROCESSES FOR PREPARING THEM

-

Page/Page column 27, (2008/06/13)

The invention relates to pyrido[3,2-e]pyrazines, to processes for preparing them, to pharmaceutical preparations which comprise these compounds and to the pharmaceutical use of these compounds, which are inhibitors of phosphodiesterase 10, as active compounds for treating diseases of mammals including a human which can be influenced by using the compounds according to the invention to inhibit phosphodiesterase 10 activity in the central nervous system. More particularly, the invention relates to the treatment of neurologic and psychiatric disorders, for example psychosis and disorders comprising cognitive deficits as symptoms.

HETEROCYCLO-SUBSTITUTED IMIDAZOPYRAZINE PROTEIN TYROSINE KINASE INHIBITORS

-

, (2008/06/13)

-

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 240815-50-3